Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
The Oncologist · 02.06.2023 · 28 (6) · 501-509
DOI: 10.1093/oncolo/oyac269 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 02.03.2023. Verfasst von Robert Motzer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Hypertension. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Merck Sharp and Dohme, Eisai Incorporated.
Abstract (Originalsprache)
Background
Lenvatinib plus pembrolizumab showed significantly improved progression-free and overall survival outcomes compared with sunitinib in patients with advanced renal cell carcinoma in the CLEAR study (NCT02811861). Here, we used CLEAR data to characterize common adverse reactions (ARs; adverse-event preferred terms grouped in accordance with regulatory authority review) associated with lenvatinib plus pembrolizumab and review management strategies for select ARs. Materials and Methods Safety data from the 352 patients who received lenvatinib plus pembrolizumab in the CLEAR study were analyzed. Key ARs were chosen based on frequency of occurrence (≥30%). Time to first onset and management strategies for key ARs were detailed.
Results
The most frequent ARs were fatigue (63.1%), diarrhea (61.9%), musculoskeletal pain (58.0%), hypothyroidism (56.8%), and hypertension (56.3%); grade ≥3 severity ARs that occurred in ≥5% of patients were hypertension (28.7%), diarrhea (9.9%), fatigue (9.4%), weight decreased (8.0%), and proteinuria (7.7%). Median times to first onset of all key ARs were within approximately 5 months (approximately 20 weeks) of starting treatment. Strategies for effectively managing ARs included baseline monitoring, drug–dose modifications, and/or concomitant medications.
Conclusion
The safety profile of lenvatinib plus pembrolizumab was consistent with the known profile of each monotherapy; ARs were considered manageable with strategies including monitoring, dose modifications, and supportive medications. Proactive and prompt identification and management of ARs are important for patient safety and to support continued treatment. Clinicaltrials.gov ID NCT02811861
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.
- Department of Medical Oncology, Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.
- Clinical Research, Merck & Co., Inc., Rahway, NJ, USA.
- Biostatistics, Eisai Inc., Nutley, NJ, USA.
ORCID-Profile: Robert Motzer
Förderung
- NCI NIH HHS
- Merck Sharp and Dohme
- Eisai Incorporated
Zitieren
APA
Motzer, R., George, S., Merchan, J. R., Hutson, T. E., Song, X., Perini, R. F., Xie, R., Bapat, U., & Puente, J. (2023). Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. The Oncologist, 28(6), 501-509. https://doi.org/10.1093/oncolo/oyac269
Vancouver
Motzer R, George S, Merchan JR, Hutson TE, Song X, Perini RF, et al. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab. The Oncologist. 2023;28(6):501-509. doi:10.1093/oncolo/oyac269
BibTeX
@article{Motzer2023,
author = {Motzer, Robert and George, Saby and Merchan, Jaime R and Hutson, Thomas E and Song, Xun and Perini, Rodolfo F and Xie, Ran and Bapat, Urmi and Puente, Javier},
title = {Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {6},
pages = {501--509},
doi = {10.1093/oncolo/oyac269}
}
EUVIMED